Member Info for Bluebelly

So from the copy & paste session you inform us:
The main distinction between expanded access and the use of an investigational drug in the usual studies covered under an IND is that expanded access uses are not PRIMARILY intended to obtain information about the safety or effectiveness of a drug".
Next statements:
'FDA may also become AWARE OF NEW SAFETY SIGNAL OR INFORMATION ABOUT EFFECTIVENESS that changes the benefit/risk ratio such that the risk is no longer acceptable for the patient. In cases such as these, individual patient expanded access for additional patients might be denied."

So I guess Safety ETC are not the primary objective, but are part of this study.

Thanks

BB

Probably due to the improved Corporate Governance from having a FTSE Main listing status.

BB

How many people have MS? Worldwide, more than 2.3 million people have a diagnosis of MS. In the United States a recently completed prevalence study, funded by the National MS Society, has estimated that nearly 1 million people over the age of 18 live with a diagnosis of MS.

How quickly does secondary progressive MS progress?
When does the transition occur? Prior to the availability of the approved disease-modifying therapies, studies indicated that 50 percent of those diagnosed with relapsing-remitting MS (RRMS) would transition to secondary-progressive MS (SPMS) within 10 years, and 90 percent would transition within 25 years.

Lets hope its a positive outcome for all concerned, something is certainly need.

BB

SJ1 - Further down the RNS they state Clinical study, that's probably incorrect as well. It's hard to find anything positive with TILS.
'This first-ever clinical study in SPMS patients, under an Individual Patient Expanded Access IND, will continue for six months to evaluate routine safety, tolerability, and neurological behaviors. The study will also examine microglial activation, by positron emission tomography (PET), immunological and neurodegenerative markers to assess clinical responses following the treatment regimen.'

93 posts on TIL non investment, and a couple of posts on your 4d investment. Glad you had the weekend off
BB

NMW - Looks like you've done your homework and such a prompt reply to SJ1.

This is the best we can expect as I believe they need more data from Mice before a proper trial in your terms is granted, as you and SJ keep informing us.
This could have amazing results and be fast tracked- Any thoughts on that.

BB

From RNS: 'The first patient with SPMS was dosed on May 24, 2021 with nasally administered Foralumab. The treatment regimen will continue for six months to examine long-term safety, tolerability and clinical responses.'

Sounds like a trial to find out the unknown!!

BB

What would you call it?

BB

Great news

On a separate note - M300's comment:
Feels like theft to me, will the compensation be additional shares or will we just continue to be taken for a ride. Think I know the answer.'
Additional shares wont really work! That would be dilution???

BB

A bit more info on Nasdaq listing requirements:
https://listingcenter.nasdaq.com/assets/initialguide.pdf

BB

A bit more info on Nasdaq listing requirements:
https://listingcenter.nasdaq.com/assets/initialguide.pdf

BB

Leddachjack & DCR.
I agree that Acustem has been a very poor process. However that is not available to new investors. What is available to a new investor is the current pipeline that has progressed further down the road to 'proof of concept' over the last 12 months and the SP is lower than we were we were last May/June.
Acustem could give us a nice surprise, if it does, I guess a lot will forgive the BOD for the delay.
I have not sold TILS and continue to increase my holding when funds allow. The new investors will turn up, some will be the bottom feeders and the others from doing a more researched approach.
I'm here hoping that inflexion point comes. Whether its 12months or more. It will be life changing for larger holders. There is risk, how much do you risk investing on TILS. A Covid trial, many patents and a large fund raise have all derisked this from 12 months ago. It's moving but slowly - It's Pharma.

BB

Foralumab - Proof of Concept - Multi $billion company.
Massive inflexion point - if TILS shows results in just one indication - Risk vs reward
Covid trial should complete by year end - Study the bio markers to assist with Proof of concept for MS/Crohns etc.
MS trial nasally, Crohns trial orally, all commencing in the next couple of months.
12 months to proof of concept, unless you're a trader, why would you be selling at 70p???

BB

Thanks for the reply RP68, a fine and reasoned post.
'a cracking case study'
A conspiracy theory from me with £10+ happy ending written all over it or Court cases and Administration for years to come.
GL in whatever you choose RP68 and I hope you use a spirtle when making your porridge.

BB

Should read: 'woolley PR interviews'.
Missed that twice, #proof-read-fail!

BB

FAO: Rokerpark68, Amica1, Sporty and all others who are struggling holding TILS at a 52 week low.
I posted this on Tuesday and I think no2 on the list is playing out, as proved by yourselves selling at this low point:
'I personally believe.
1. We are being held back by trading algo's and standard practices on trading platforms. Which is allowing investors to load up below the radar. HNWI and II's buy of the sell side with Direct Market Access (DMA) . With a negative bias on the Algo's we are driven down. At some point the Algo will change (when the FTSE investors have had their fill).
2. The BoD are compliant, they are briefed on joining the FTSE of the way ahead ( Boredom, Boredom, lack of clarity). This is a longer term plan that normally rids a share of PI's at a low SP, who are not willing to hold for the longer term. Imagine the amount of investment houses that have employees with multiple accounts (I could be one), posting fear when they need to buy or ramping when they need to sell.
3. At some point in the future all the plans will fall into place as stated in the wholley PR interviews. The share will rise to new levels and TR1's will be released as HNWI & II's purchase a few hundred shares and cross the 3% line.

Today was possibly the first minor bad news RNS I can remember. I expected a greater fall as they have the excuse - GC's bonus and lack of Acustem news, but I don't think they can shake any of the holders out. I have no cash to buy more and I will not sell.

I don't want to look back and say if only I'd held and looked away for 24 months (12 down already).

Nasdaq at 80p, UK at 71p, Acustem to come. I'm not happy, but happy to hold.'

That was Tuesday, since then we have had loads of (new???) info posted all intended to show TILS in a bad light, theft of blood samples, BMS failure of drug/death/sickness.

We now read on the BB that some medium to long term holders have sold/reduced. That is a shame as Rokerpark68 states he had 30+ years working in the investment industry. Read note 2 again, have you witnessed this type of thing in your long career RK68?
Is this a Ponzi scam or a company that the city want in on? Who knows, but I will be holding which ever way it plays out.
GLAH

BB

Some incredible info coming out from this thread.
Prof Chris McGuigan the co founder of Tils, the derivative of his work led directly to Remdesevir.
The trials process is there to eliminate these problems. Were BMS early movers, at what stage did they buy Inhibitex?

Good research Sporty, I hope it doesn't effect your position. This is not the time to be selling. The director buy means nothing in its value effectively, but I do see us recovering strongly from around here. We were listed on the main market for a reason. If they (FTSE) did not like the look of TILS and it's pipeline, the listing would have seen delays or caveats to complete before it occurred.

On the subject of GC's bonus. I do remember a post by someone, who mentioned that bonus target being hit in August due to the fund raise and SP. If it was posted on a BB, you can be sure the FTSE DD team were aware. They probably didn't like it, but they still listed TILS, they see value.
Stay strong, ignore the noise. If funds allow buy some more at these levels. I've no available cash at present, but I do hold some Tax money due in January 22. Gift horse and all that!!!

BB

I personally believe.
1. We are being held back by trading algo's and standard practices on trading platforms. Which is allowing investors to load up below the radar. HNWI and II's buy of the sell side with Direct Market Access (DMA) . With a negative bias on the Algo's we are driven down. At some point the Algo will change (when the FTSE investors have had their fill).
2. The BoD are compliant, they are briefed on joining the FTSE of the way ahead ( Boredom, Boredom, lack of clarity). This is a longer term plan that normally rids a share of PI's at a low SP, who are not willing to hold for the longer term. Imagine the amount of investment houses that have employees with multiple accounts (I could be one), posting fear when they need to buy or ramping when they need to sell.
3. At some point in the future all the plans will fall into place as stated in the wholley PR interviews. The share will rise to new levels and TR1's will be released as HNWI & II's purchase a few hundred shares and cross the 3% line.

Today was possibly the first minor bad news RNS I can remember. I expected a greater fall as they have the excuse - GC's bonus and lack of Acustem news, but I don't think they can shake any of the holders out. I have no cash to buy more and I will not sell.

I don't want to look back and say if only I'd held and looked away for 24 months (12 down already).

Nasdaq at 80p, UK at 71p, Acustem to come. I'm not happy, but happy to hold.

BB

Hi Iceman
I'm in a similar position to yourself, however, I have 30,000 Acustem that could reduce loss slightly or significantly. 77p and I will be about evens, can't see that price on issue, but nobody knows anything yet. Are you due to receive any Acustem?
Surprisingly it was still a red week, lets hope this is the reversal of this 15 week short term downtrend or 10 month long term downtrend. I do believe the next 12-24 months will see us at levels not previously seen, as long as just some of the trials are positive . Any thoughts this?

BB

Ignore my last post.
The FTSE itself states it is Main Market:
https://www.londonstockexchange.com/stock/TILS/tiziana-life-sciences-plc/company-page

I also checked Banco Santander valued at £48bn, they are also unclassified.
We can stay unclassified to at least £50bn m/cap. That's handy - £255/share.

GLA

BB

According to this website Tils is unclassified (Around 578th FTSE position level when at 81p).
I'm sure it was listed as a FTSE small cap last time I look.
http://www.stockchallenge.co.uk/ftse.php

May be TILS has plans to exit the FTSE and be on the NASDAQ only alongside Acustem.
That was a joke! I don't want to start a rumour.
Anyone with any knowledge on why we are highlighted in white as unclassified on that list?

BB